Pfiz­er ter­mi­nates PhI­II study of rare car­dio­vas­cu­lar drug picked up in $11.4B Ar­ray ac­qui­si­tion

While Pfiz­er’s $11.4 bil­lion ac­qui­si­tion of Ar­ray Bio­Phar­ma in the sum­mer of 2019 was main­ly fo­cused on on­col­o­gy, name­ly Braftovi and Mek­tovi, there were …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.